The Efficacy and Safety of Avanafil During a Treatment of Male Erectile Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Syah Mirsya Warli,Steven Steven,Dhirajaya Dharma Kadar,Fauriski Febrian Prapiska,Ginanda Putra Siregar
DOI: https://doi.org/10.2147/TCRM.S419408
2023-07-19
Therapeutics and Clinical Risk Management
Abstract:Syah Mirsya Warli, 1, 2 Steven Steven, 3 Dhirajaya Dharma Kadar, 1 Fauriski Febrian Prapiska, 1 Ginanda Putra Siregar 1 1 Division of Urology, Department of Surgery, Faculty of Medicine, Universitas Sumatera Utara – Haji Adam Malik General Hospital, Medan, Indonesia; 2 Department of Urology, Universitas Sumatera Utara Hospital, Universitas Sumatera Utara, Medan, Indonesia; 3 Department of Urology, Faculty of Medicine, Universitas Indonesia - Haji Adam Malik General Hospital, Medan, Indonesia Correspondence: Syah Mirsya Warli, Division of Urology, Department of Surgery, Faculty of Medicine, Universitas Sumatera Utara, Dr. Mansyur No. 5 Medan, North Sumatera, 20154, Indonesia, Tel +6261-8364930, Email Purpose: Erectile dysfunction (ED) contributes to a large burden and impairs the quality of life among males. Avanafil appears to be a promising treatment for ED; however, its efficacy and safety profile remain unclear. This study aimed to evaluate the efficacy and safety of avanafil for the treatment of ED. Patients and Methods: An extensive search of PubMed, ScienceDirect, Web of Science, and Embase databases with 11 publications was performed, with outcomes evaluated are International Index of Erectile Function – Erectile Function (IIEF-EF), Sexual Encounter Profile (SEP), and Treatment-Emergent Adverse Events (TEAE). Statistical parameter Mean Difference (MD) and Risk Ratio (RR) with 95% Confidence Interval (CI) were used to measure effect size. Results: The pooled estimates demonstrated that changes in IIEF-EF function (MD=4.39, 95% CI [3.41, 5.37], p< 0.001), SEP-2 (RR=3.43, 95% CI [2.79, 4.22], p< 0.001), SEP-3 (RR=2.30, 95% CI [2.01, 2.62], p< 0.001), and TEAE (RR=1.49, 95% CI [1.12, 1.96], p=0.005) were significantly higher in the avanafil group than in the placebo group. Moreover, 200 mg avanafil was superior to that mg 100 mg-avanafil, indicated by the IIEF-EF score (MD=− 1.15, 95% CI [− 1.40, − 0.89], p< 0.001). In contrary, there were no significant differences in SEP-2 (RR=0.90, 95% CI [0.75, 1.08], p=0.26), SEP-3 (RR=0.92, 95% CI [0.81, 1.05], p=0.21) and TEAE (RR=1.00, 95% CI [0.87, 1.15], p=0.99) for both 100 mg and 200 mg doses. Conclusion: This review highlights the potential use of this drug in ED treatment. Further large-scale Randomized Controlled Trials investigations involving various racial groups are required to confirm these findings. Graphical Keywords: avanafil, erectile dysfunction, meta-analysis, systematic review, randomized controlled trial Graphical Erectile dysfunction (ED), the most prevalent sexual health issue among men, is defined as a recurrent inability to establish or maintain sufficient penile erection for satisfied-sexual performance. 1 The global prevalence of ED ranges from 3% to 76.5%. 2 Approximately 40% of males have suffered some form of erectile dysfunction by the time reaching their forties, and this number is predicted to grow by approximately 10% per decade. 3 Recent research indicates that the frequency of ED among young men is as high as 30%. 4 Cardiovascular disease, diabetes, hyperlipidemia, hypertension, smoking, obesity are well known risk factors for ED. 1 Although ED is not a life-threatening condition, it constitutes a large burden due to its high prevalence and impact on quality of life, becoming a risk factor for the development of cardiovascular disease, dementia, and all-cause mortality. 5 Since the discovery and introduction of sildenafil, a phosphodiesterase type-5 (PDE-5) inhibitor, has been considered as the first-line therapy for treating ED in a wide range of patients with diverse etiologies of sexual dysfunction. 6 Currently, four drugs are approved by the Food and Drug Administration (FDA) for the treatment of ED: sildenafil, vardenafil, tadalafil, and the most recent addition, avanafil. 7 However, owing to sporadic failures and unpleasant side effects, many patients are dissatisfied with initial PDE-5 inhibitors (sildenafil, vardenafil, and tadalafil). As a new PDE-5 inhibitor with strong PDE-5 inhibition, it is more promising than the others because of its selectivity and minimal adverse events. 8 Avanafil has been identified to be a promising treatment for ED. Avanafil was approved for the treatment of ED in the US and Europe in 2012 and 2013. 9 This drug also has the advantages of rapid onset of action (Tmax 35 min) and short half-life (< 1.5 h) compared to other PDE5 inhibitors. 10 It works by mediating the breakdown of cyclic guanosine monophosphate (cGMP), inducing smooth muscle relaxation in t -Abstract Truncated-
health care sciences & services